购物车 
-
17β-雌二醇
NMR and HPLC COA下载 MSDS下载 - Names：
17beta-Estradiol, Selective agonist of ER receptor
- CAS号：
50-28-2
MDL Number： MFCD00003693 - MF(分子式)： C18H24O2 MW(分子量)： 272.38
- EINECS:200-023-8 Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
17β-雌二醇(17β-Estradio,50-28-2)是雌二醇的合成形式，雌激素是类固醇性激素，对维持女性的生育能力和继发性特征至关重要，可以用作激素替代疗法。雌二醇结合并激活特定的核受体,雌二醇表现出温和的合成代谢和代谢特性，并增加血液凝固性。 它可能在免疫和炎症过程中起作用。
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| SC0285-25g | 25g | 98% | ¥ 1894.00 | ¥ 1894.00 | 716 | 1-2days | ¥ 0.00 | |
| SC0285-5g | 5g | 98% | ¥ 450.00 | ¥ 450.00 | 232 | 1-2days | ¥ 0.00 | |
| SC0285-1g | 1g | 98% | ¥ 158.00 | ¥ 158.00 | 90 | 1-2days | ¥ 0.00 |
| 中文别名 | 17β-雌二醇，beta-雌二醇；ER受体选择性激动剂;雌二醇(50-28-2);雌(甾)二醇; 雌甾-1,3,5-(10)-三烯-3β,17β-二醇; BATA-雌二醇; BETA-1,3,5(10)-三烯-3,17Β-二醇; beta-雌二醇; β-雌二醇; 17Β-雌二醇; 3,17Β-二羟基-1,3,5(10)-雌甾三烯-3,17Β-二醇; Β-雌激素; 雌甾-1,3,5(10)-三烯-3,17Β-二醇; 雌甾二醇; 雌二醇; 雌素二醇; 雌性二醇; 二羟基雌激素酮; 雌甾-1,3,5(10)-三烯3,17Β-二醇,ESTRA-1,3,5(10)-TRIENE-3,17Β-DIOL |
| 英文别名 | 17beta-Estradiol, Selective agonist of ER receptor;β-Estradiol(CAS:50-28-2),estradiol, beta-Estradiol, 17beta-Estradiol, Oestradiol, Dihydrofolliculin, Estrace,, Ovocyclin, progynon, Dihydrotheelin |
| CAS号 | 50-28-2 |
| Inchi | InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1 |
| InchiKey | VOXZDWNPVJITMN-ZBRFXRBCSA-N |
| 分子式 Molecular Weight | C18H24O2 |
| 分子量 Formula | 272.38 |
| 溶解度Solubility | Soluble in dimethyl sulfoxide, ethanol , water, phosphate buffer saline, dimethyl formamide, acetone, dioxane and alkali hydroxides. Slightly soluble in vegetable oils. |
| 性状 | 白色 至灰白色结晶粉末 |
| 储藏条件 Storage conditions | 室温、干燥、密封保存。 |
17β-雌二醇(17β-Estradio,50-28-2)毒理学资料：
据称，氟维西平治疗与多达15％的患者血清酶升高有关，但升高通常是无症状的，短暂的和轻度的，很少需要调整剂量或停药。 ALT升高超过正常上限的5倍，仅发生在1％至2％的患者中。 然而，尚未有关于氟维司群治疗期间血清酶升高的时间和过程的细节。 此外，在氟维司群的预许可对照试验中，没有报告临床上明显的黄疸性肝损伤病例，自从美国批准氟维司群以来，还没有发表过任何报道，更广泛地使用了该药物。
17β-雌二醇(17β-Estradio,50-28-2)实验注意事项：
1.使用50-28-2实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.使用50-28-2实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品50-28-2的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品50-28-2时尽量采用多个药勺分别使用，使用后清洗干净。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
大规格定制：定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:雌二醇蒸汽压,雌二醇合成,雌二醇标准,雌二醇应用,雌二醇合成,雌二醇沸点,雌二醇闪点,雌二醇用途,雌二醇溶解度,雌二醇价格,雌二醇作用,雌二醇结构式,雌二醇用处
据称，氟维西平治疗与多达15％的患者血清酶升高有关，但升高通常是无症状的，短暂的和轻度的，很少需要调整剂量或停药。 ALT升高超过正常上限的5倍，仅发生在1％至2％的患者中。 然而，尚未有关于氟维司群治疗期间血清酶升高的时间和过程的细节。 此外，在氟维司群的预许可对照试验中，没有报告临床上明显的黄疸性肝损伤病例，自从美国批准氟维司群以来，还没有发表过任何报道，更广泛地使用了该药物。
17β-雌二醇(17β-Estradio,50-28-2)实验注意事项：
1.使用50-28-2实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.使用50-28-2实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品50-28-2的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品50-28-2时尽量采用多个药勺分别使用，使用后清洗干净。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
大规格定制：定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:雌二醇蒸汽压,雌二醇合成,雌二醇标准,雌二醇应用,雌二醇合成,雌二醇沸点,雌二醇闪点,雌二醇用途,雌二醇溶解度,雌二醇价格,雌二醇作用,雌二醇结构式,雌二醇用处
| 产品说明 | 雌二醇(50-28-2)是雌二醇的合成形式,雌激素是类固醇性激素,雌二醇对维持女性的生育能力和继发性特征至关重要.雌二醇溶解度,雌二醇MSDS详见主页. |
| Introduction | β-Estradiol(雌二醇,50-28-2) is a synthetic form of estradiol, a steroid sex hormone vital to the maintenance of fertility |
| Application1 | 雌二醇是雌性内源性循环的天然激素。 |
| Application2 | 经前期卵巢分泌的只要雌激素 |
| Application3 | 在青春期靠调控基因转录和蛋白质合成指导雌性表现型和胚胎的发育，也诱导促性腺激素的生成，诱导排卵 |
| 警示图 | |
| 危险性 | warning |
| 危险性警示 | Not Available |
| 安全声明 | H350,H400 |
| 安全防护 | P201,P273,P308+P313 |
| 备注 | 避免吸入，误食以及与皮肤接触 |
| Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes Endocrinology 2020-09-01 32730568 |
| Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer Cancers 2020-08-18 32824674 |
| Potential Influence of Menstrual Status and Sex Hormones on female SARS-CoV-2 Infection: A Cross-sectional Study from Multicentre in Wuhan, China Clinical infectious diseases : an official publication |
| The gendered impact of coronavirus disease (COVID-19): do estrogens play a role? The European journal of contraception & reproductive health care : the official journal of the European Society of Cont |
| Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by |
1.Translational studies of estradiol and progesterone in fear and PTSD/PMID 32158516; European journal of psychotraumatology 2020; 11(1):1723857 (Review Article)/Name matches: progesterone estradiol
Abstract in English, Spanish, Chinese：Translational models of fear have greatly informed our understanding of PTSD and its underlying fear circuitry. One of the most replicated findings in the field is the two-fold higher PTSD incidence in females compared to males. While sociocultural factors play a role, the most robust biological influencers to date are gonadal hormones, such as estradiol and progesterone, which fluctuate across the menstrual cycle. Among studies that account for these hormones, most do so in isolation or collect both and only report one. Variation in study findings suggests that the ratio between these two hormones (the P/E ratio) may be an important and missing variable to further understand gonadal hormone influences on fear. Here we review cross-species examinations of fear and PTSD, within the contexts of estradiol and progesterone as well as P/E ratios that were calculated based on extant literature. We then provide recommendations for best practices in assay methods and reporting to improve research on the P/E ratio in fear and PTSD. Ultimately, greater understanding of this important variable will advance efforts to characterize gonadal hormone influences on fear learning processes in humans and animals.
2.Differential effects of chronic 17β-oestradiol treatment on rat behaviours relevant to depression/PMID 30311279; Journal of neuroendocrinology 2018 11; 30(11):e12652 (Review Article)/Name matches: progesterone 17beta-oestradiol
Abstract：Sex differences are a prominent feature of the pathophysiology of psychiatric disorders, such as major depressive disorder, which affects women at a higher incidence than men. Research suggests that the most potent endogenous oestrogen, 17β-oestradiol, may have therapeutic potential in treating depression. However, preclinical studies have produced mixed results, likely as a result of various methodological factors such as treatment duration. The present study aimed to investigate the effects of ovariectomy and chronic 17β-oestradiol treatment via a s.c. silastic implant on behaviours relevant to depression in adult female Sprague-Dawley rats. Rats were assessed in the forced swim test, saccharin preference test and novel object recognition memory test, as well as for possible confounding behaviours, including locomotion and anxiety (open field test) and motivation and anxiety (novelty suppressed feeding test). Treatment effects were verified using body and uterus weight, as well as serum concentrations of 17β-oestradiol, progesterone and testosterone. Compared to ovariectomised rats, chronic 17β-oestradiol treatment enhanced saccharin preference and novel object recognition performance. There were no group differences in passive or active coping behaviour when assayed using the forced swim test. Taken together, these results support an antidepressant-like action of oestrogens but highlight that the beneficial effects of chronic 17β-oestradiol treatment may be related to specific depression-related symptoms, particularly anhedonia and memory.
3.A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause/PMID 31282768; Expert review of clinical pharmacology 2019 Aug; 12(8):729-739 (Review Article)/Name matches: progesterone 17beta-estradiol
Abstract：Introduction: Many women seek treatment to alleviate menopausal vasomotor symptoms (VMS). Numerous women use combination compounded hormone therapy (CHT) to achieve the benefits of estrogen/progesterone for endometrial protection. TX-001HR is a combination of bioidentical 17β-estradiol (E2) and progesterone (P4) in a single capsule designed for continuous daily use to treat moderate to severe VMS. Areas covered: This drug profile describes the efficacy and safety of 4 doses of this E2/P4 (mg/mg: 1/100, 0.5/100, 0.5/50, 0.25/50) for treating moderate to severe VMS in menopausal woman with a uterus. Expert opinion: In REPLENISH (NCT01942668), the two highest doses of TX-001HR significantly reduced VMS frequency and severity at 4 and 12 weeks versus placebo (co-primary endpoints); all doses met the primary endpoint of endometrial safety. Rates of amenorrhea were high and improved over time; the Menopause Quality of Life and Medical Outcomes Study-Sleep instruments improved with E2/P4. TX-001HR was well tolerated and had no clinically significant impact on vital signs, metabolic or coagulation parameters, or breast safety. The combination bioidentical E2/P4 capsule (1 mg/100 mg dose was FDA-approved as Bijuva in October 2018) may provide a safe, effective, rigorously studied alternative for women with a uterus who prefer CHT for relief of VMS.
Abstract in English, Spanish, Chinese：Translational models of fear have greatly informed our understanding of PTSD and its underlying fear circuitry. One of the most replicated findings in the field is the two-fold higher PTSD incidence in females compared to males. While sociocultural factors play a role, the most robust biological influencers to date are gonadal hormones, such as estradiol and progesterone, which fluctuate across the menstrual cycle. Among studies that account for these hormones, most do so in isolation or collect both and only report one. Variation in study findings suggests that the ratio between these two hormones (the P/E ratio) may be an important and missing variable to further understand gonadal hormone influences on fear. Here we review cross-species examinations of fear and PTSD, within the contexts of estradiol and progesterone as well as P/E ratios that were calculated based on extant literature. We then provide recommendations for best practices in assay methods and reporting to improve research on the P/E ratio in fear and PTSD. Ultimately, greater understanding of this important variable will advance efforts to characterize gonadal hormone influences on fear learning processes in humans and animals.
2.Differential effects of chronic 17β-oestradiol treatment on rat behaviours relevant to depression/PMID 30311279; Journal of neuroendocrinology 2018 11; 30(11):e12652 (Review Article)/Name matches: progesterone 17beta-oestradiol
Abstract：Sex differences are a prominent feature of the pathophysiology of psychiatric disorders, such as major depressive disorder, which affects women at a higher incidence than men. Research suggests that the most potent endogenous oestrogen, 17β-oestradiol, may have therapeutic potential in treating depression. However, preclinical studies have produced mixed results, likely as a result of various methodological factors such as treatment duration. The present study aimed to investigate the effects of ovariectomy and chronic 17β-oestradiol treatment via a s.c. silastic implant on behaviours relevant to depression in adult female Sprague-Dawley rats. Rats were assessed in the forced swim test, saccharin preference test and novel object recognition memory test, as well as for possible confounding behaviours, including locomotion and anxiety (open field test) and motivation and anxiety (novelty suppressed feeding test). Treatment effects were verified using body and uterus weight, as well as serum concentrations of 17β-oestradiol, progesterone and testosterone. Compared to ovariectomised rats, chronic 17β-oestradiol treatment enhanced saccharin preference and novel object recognition performance. There were no group differences in passive or active coping behaviour when assayed using the forced swim test. Taken together, these results support an antidepressant-like action of oestrogens but highlight that the beneficial effects of chronic 17β-oestradiol treatment may be related to specific depression-related symptoms, particularly anhedonia and memory.
3.A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause/PMID 31282768; Expert review of clinical pharmacology 2019 Aug; 12(8):729-739 (Review Article)/Name matches: progesterone 17beta-estradiol
Abstract：Introduction: Many women seek treatment to alleviate menopausal vasomotor symptoms (VMS). Numerous women use combination compounded hormone therapy (CHT) to achieve the benefits of estrogen/progesterone for endometrial protection. TX-001HR is a combination of bioidentical 17β-estradiol (E2) and progesterone (P4) in a single capsule designed for continuous daily use to treat moderate to severe VMS. Areas covered: This drug profile describes the efficacy and safety of 4 doses of this E2/P4 (mg/mg: 1/100, 0.5/100, 0.5/50, 0.25/50) for treating moderate to severe VMS in menopausal woman with a uterus. Expert opinion: In REPLENISH (NCT01942668), the two highest doses of TX-001HR significantly reduced VMS frequency and severity at 4 and 12 weeks versus placebo (co-primary endpoints); all doses met the primary endpoint of endometrial safety. Rates of amenorrhea were high and improved over time; the Menopause Quality of Life and Medical Outcomes Study-Sleep instruments improved with E2/P4. TX-001HR was well tolerated and had no clinically significant impact on vital signs, metabolic or coagulation parameters, or breast safety. The combination bioidentical E2/P4 capsule (1 mg/100 mg dose was FDA-approved as Bijuva in October 2018) may provide a safe, effective, rigorously studied alternative for women with a uterus who prefer CHT for relief of VMS.
对不起，暂无产品评价！
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
怎么做细胞爬片免疫组化染色实验
细胞爬片免疫组化染色，是通过细胞爬片是让玻片浸在细胞培养基内，细胞在玻片上生长，主要用于组织学，免疫组织化学...
2020/7/20 22:04:33
提取病毒RNA的实验方法
提取病毒RNA方法分别有：异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
细胞培养耗材技术领先性
细胞培养板行业面临的核心痛点是：常规TC处理后表面亲水角随时间衰减，影响长期培养稳定性，BIOFOUNT高分...
2026/4/28 15:12:51
细胞培养耗材关键性能
细胞培养板的水接触角作为表面润湿性的核心指标，直接影响细胞贴壁、增殖、分化及功能表达，其中40°（低接触角/...
2026/4/28 14:52:44
chelex 100树脂国产替代之路-BIOFOUNT范德生物
Chelex 100螯合离子交换树脂对铜、铁和其他重金属?的偏好显著高于对钠、钾等一价阳离子的偏好。它对二价...
2025/11/4 14:22:46
9月开学季——助研新学期 范德送好礼
2025/8/28 15:30:55
Waxfilm 实验室封口膜：技术与国际市场的双重突破
在实验室耗材领域，封口膜是保障实验准确性与稳定性的关键产品之一。近年来，Waxfilm?实验室封口膜凭借其卓...
2025/5/13 13:03:40
Waxfilm实验室封口膜的5大突破
Waxfilm实验室封口膜作为生物功能膜领域的国产技术突破和品牌突破，是生物领域中国技术发展的缩影。
2025/5/6 17:02:07
各种微流控芯片键合方法的优缺点
微流控芯片键合：目前主要有激光焊接、热压键合、胶键合、超音波焊接，每种方法都有各自的优缺点。本文主要介绍聚酯...
2023/7/28 10:43:09
新一代微流控键合解决方案
微流控键合解决方案：微流控芯片制造的一个重要环节，也是最容易被忽视的--芯片键合。其中一个重要因素是：微流控...
2023/7/27 12:44:28
